Valuation: Black Diamond Therapeutics, Inc.

Market Cap 112M 96.65M 90.26M 82.8M 156M 10.63B 158M 1.06B 416M 5.33B 420M 410M 17.62B P/E 2026 *
-3.56x
P/E 2027 * -1.94x
Enterprise Value 112M 96.65M 90.26M 82.8M 156M 10.63B 158M 1.06B 416M 5.33B 420M 410M 17.62B EV / Sales 2026 *
17.9x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 day+1.56%
1 week+15.38%
Current month+15.38%
1 month-6.25%
3 months-28.31%
6 months-13.53%
Current year-19.75%
1 week 1.68
Extreme 1.675
1.98
1 month 1.62
Extreme 1.62
1.98
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
10.47
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 16/09/2023
Chief Tech/Sci/R&D Officer 51 11/08/2021
Director of Finance/CFO 41 07/10/2024
Director TitleAgeSince
Director/Board Member 61 01/03/2017
Director/Board Member 47 01/12/2019
Director/Board Member 49 01/12/2018
Date Insider Type Main position Quantity % Market Cap.
20/3/26 Free

Director

6,919 0.0121%
21/1/26 Free

Chief Technology Officer

250,000 0.4388%
21/1/26 Free

Founder

250,000 0.4388%
Change 5-day change 1-year change 3-year change Capi.($)
+1.56%+15.38%-14.47%-42.31% 112M
+8.49%+20.55%+69.74%+109.30% 68.12B
+1.25%+2.44%+32.55%+72.63% 55.18B
-1.09%+32.96%+19.95%+499.45% 28.63B
+2.72%+3.41%-15.88%-4.90% 23.53B
+10.83%+18.38%+52.76%+4.58% 23.99B
+6.50%+7.56%+38.20%-21.33% 18.45B
-3.88%+16.98%+199.30%+354.30% 15.83B
+6.20%+11.51%+34.94%+681.88% 16.44B
+3.58%+1.96%+44.61%+167.01% 13.4B
Average +3.62%+12.05%+46.17%+182.06% 26.37B
Weighted average by Cap. +4.36%+13.10%+49.45%+168.40%

Financials

2026 *2027 *
Net sales 6.25M 5.41M 5.05M 4.63M 8.71M 595M 8.85M 59.23M 23.25M 298M 23.47M 22.96M 986M -
Net income -19.97M -17.27M -16.13M -14.8M -27.83M -1.9B -28.27M -189M -74.28M -952M -74.98M -73.34M -3.15B -69.99M -60.54M -56.53M -51.86M -97.55M -6.66B -99.09M -663M -260M -3.34B -263M -257M -11.04B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
07/08/26 US$1.950 +1.56% 599,920
06/08/26 US$1.920 +7.26% 748,139
05/08/26 US$1.790 +0.56% 384,234
04/08/26 US$1.780 +2.59% 917,200
03/08/26 US$1.735 +2.66% 429,635
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.950USD
Average target price
9.857USD
Spread / Average Target
+405.49%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock